BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27287719)

  • 21. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.
    Zhou L; Opalinska J; Verma A
    Cell Cycle; 2007 Mar; 6(5):534-7. PubMed ID: 17351344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
    Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
    Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
    Czibere A; Prall WC; Zerbini LF; Jäger M; Kobbe G; Knipp S; Libermann TA; Haas R; Aivado M
    Br J Haematol; 2006 Nov; 135(3):355-7. PubMed ID: 16978222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
    Verstovsek S; Estey E; Manshouri T; Keating M; Kantarjian H; Giles FJ; Albitar M
    Leuk Lymphoma; 2001 Jul; 42(3):511-6. PubMed ID: 11699417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Grosjean-Raillard J; Adès L; Boehrer S; Tailler M; Fabre C; Braun T; De Botton S; Israel A; Fenaux P; Kroemer G
    Apoptosis; 2008 Sep; 13(9):1148-61. PubMed ID: 18670883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes.
    Shahjahan M; Dunphy CH; Ewton A; Zu Y; Monzon FA; Rice L; Chang CC
    Am J Clin Pathol; 2008 Oct; 130(4):635-41. PubMed ID: 18794058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
    Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
    Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
    Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
    Reikvam H; Hatfield KJ; Lassalle P; Kittang AO; Ersvaer E; Bruserud Ø
    Expert Opin Investig Drugs; 2010 Feb; 19(2):169-83. PubMed ID: 20050812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
    Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
    Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.